NEONC TECHNOLOGIES HOLDINGS, INC.
Business
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing novel drug delivery methods and drug candidates for intracranial malignancies, including primary and secondary brain cancers. The company's lead products are NEO100 (intranasal perillyl alcohol) in Phase IIa trials for malignant glioma and meningioma, and NEO212 (a conjugate of perillyl alcohol and temozolomide) in Phase I/II trials for brain cancers and metastases. NeOnc operates as a drug developer relying on contract manufacturers, with no approved commercial products, and recently acquired AI-driven drug discovery and 3D bioprinting technology platforms to enhance preclinical research.
Summary from 10-K filed 2026-07-01
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Revenue | 39,990 | 83,000 | |
| Research and development | 4 | 3 | |
| Legal and professional | 2 | 2 | |
| General and administrative | 5 | 2 | |
| Share based compensation | 36 | — | |
| Advisory fees principally related parties | 12 | 500,000 | |
| Total Operating Expenses | 58 | 7 | |
| Loss From Operations | −58 | −7 | |
| Interest and other income | 327,582 | 16,133 | |
| Grant income | 71,247 | — | |
| Amortization of debt issuance costs | −1 | −145,097 | |
| Interest expense | −3 | −3 | |
| Loss on extinguishment of Bridge loan related party | — | −2 | |
| Loss on change in fair value of derivative liability related to sales of common stock through equity line of credit | −689,543 | — | |
| Net Loss | −62 | −12 | |
| Basic net loss per common share | −3.2 | −0.69 | |
| Diluted net loss per common share | −3.2 | −0.69 | |
| Weighted average shares used in computing basic net loss per common share | 19 | 17 | |
| Weighted average shares used in computing diluted net loss per common share | 19 | 17 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 58,729 | 64,893 | — | |
| Deferred offering costs current | 75,082 | 1 | — | |
| Debt issuance costs current | 671,804 | 671,804 | — | |
| Prepaid expenses and other current assets | 583,096 | 386,559 | — | |
| Total Current Assets | 1 | 2 | — | |
| Debt issuance costs net of current portion | 526,701 | 1 | — | |
| Right of use asset operating lease | 361,045 | 23,526 | — | |
| Other assets | 47,177 | — | — | |
| Intangible asset | 500,000 | — | — | |
| Total Assets | 3 | 3 | — | |
| Accounts payable and accrued expenses | 6 | 3 | — | |
| Accounts payable related parties | 996,087 | 628,277 | — | |
| Accrued advisory fee related party | 2 | — | — | |
| Litigation settlement payable | 5 | 5 | — | |
| Convertible promissory notes, net of discount | 6 | — | — | |
| Accrued compensation | 255,099 | 734,874 | — | |
| Lease liability, current | 71,131 | 24,722 | — | |
| Total Current Liabilities | 20 | 9 | — | |
| Lease liability, net of current portion | 290,682 | — | — | |
| Total Liabilities | 20 | 9 | — | |
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares were issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — | — | |
| Common stock, $0.0001 par value, 100,000,000 shares authorized; 21,990,688 and 18,090,526 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 2,198 | 1,809 | — | |
| Treasury stock 302,766 shares of common stock | −3 | — | — | |
| Additional paid in capital | 98 | 45 | — | |
| Accumulated deficit | −113 | −51 | — | |
| Total Stockholders Deficit | −18 | −6 | −14 | |
| Total Liabilities and Stockholders Deficit | 3 | 3 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Increase in bridge loan expenses paid by bridge loan provider on behalf of the Company | — | 476,393 | |
| Accretion of original issue discount on related party loan | 300,000 | 3 | |
| Accretion of original issue discount on convertible promissory note | 2 | — | |
| Write off deferred issuance costs | — | 703,796 | |
| Loss on extinguishment of bridge loan | — | 2 | |
| Loss on change in fair value of derivative liability | 689,543 | — | |
| Amortization of debt issuance costs | 1 | 145,097 | |
| Amortization of right of use asset | 36,461 | 245,945 | |
| Prepaid expenses | −196,535 | −123,627 | |
| Other assets | −47,177 | — | |
| Accrued compensation | −479,775 | 56,131 | |
| Lease liability | −12,167 | −244,748 | |
| Accrued advisory fee related party | 2 | — | |
| Accounts payable and accrued expenses | 1 | 2 | |
| Net cash used in operating activities | −20 | −4 | |
| Purchases of intangible asset | −500,000 | — | |
| Net cash used in investing activities | −500,000 | — | |
| Proceeds from the sale of common stock, net of costs | 11 | 5 | |
| Proceeds from the sale of common stock private placement | 1 | — | |
| Proceeds from related party loan | 300,000 | 892,028 | |
| Repayment of related party loan | −600,000 | −791,077 | |
| Deferred offering costs | — | −469,793 | |
| Proceeds from sale of common stock pursuant to equity purchase agreement | 5 | — | |
| Proceeds from convertible notes payable | 4 | — | |
| Net cash provided by financing activities | 21 | 4 | |
| Net (decrease) increase in cash and cash equivalents | −6,164 | 33,031 | |
| Original issue discount on bridge loan related party | — | 1 | |
| Right of use asset, at lease commencement | — | 536,605 | |
| Share issued in connection with advisory services | 557,060 | — | |
| Cashless exercise of warrants | 2 | — | |
| Reclassified deferred offering costs to APIC at the completion of the offering | 1 | — | |
| Increase in bridge loan payable prepaid and deferred offering costs paid directly by bridge loan provider on behalf of the Company | — | 31,346 | |
| Conversion of bridge loan to common stock | — | 12 | |
| Conversion of accrued compensation | — | 412,500 | |
| Conversion of account payable to common stock | — | 2 | |
| Tax effect related to net share settlement of equity awards | 3 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is NEONC TECHNOLOGIES HOLDINGS, INC.'s CIK number?
NEONC TECHNOLOGIES HOLDINGS, INC.'s SEC CIK number is 0001979414 (1979414). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find NEONC TECHNOLOGIES HOLDINGS, INC.'s SEC filings?
All of NEONC TECHNOLOGIES HOLDINGS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did NEONC TECHNOLOGIES HOLDINGS, INC. last report earnings?
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) most recently filed an earnings 8-K with the SEC on May 18, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001829126-26-005421). This is NEONC TECHNOLOGIES HOLDINGS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is NEONC TECHNOLOGIES HOLDINGS, INC.'s most recent earnings 8-K?
NEONC TECHNOLOGIES HOLDINGS, INC.'s latest earnings 8-K (Item 2.02) was filed May 18, 2026 under accession 0001829126-26-005421. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View NEONC TECHNOLOGIES HOLDINGS, INC.'s latest earnings 8-K →
Look up any company's CIK number →